Pharmacologic profile of ropinirole: a nonergoline dopamine agonist.

The use of dopamine agonists as monotherapy or in combination with levodopa in the treatment of Parkinson's disease (PD) allows for reduction or limitation of the levodopa dose, potentially delaying the onset or reducing the severity of late motor complications. Ropinirole is a new nonergoline dopamine agonist that binds specifically to D2-like receptors with a selectivity similar to that of dopamine (D3 > D2 > D4). The chemical structure of ropinirole has the potential to maintain a structure-activity relationship similar to that of dopamine and other effective dopamine agonists without producing ergot-related adverse effects. Ropinirole has demonstrated efficacy in two standard preclinical models of PD and has shown a very low propensity to induce dyskinesia in these studies. This latter property is of potential clinical importance for pharmacotherapy of early PD. This article will present the importance of pharmacologic specificity of dopamine agonists along with the basic pharmacologic characteristics of ropinirole that may contribute to its efficacy in the treatment of PD.
AuthorsI F Tulloch
JournalNeurology (Neurology) Vol. 49 Issue 1 Suppl 1 Pg. S58-62 (Jul 1997) ISSN: 0028-3878 [Print] UNITED STATES
PMID9222275 (Publication Type: Journal Article, Review)
Chemical References
  • Antiparkinson Agents
  • Dopamine Agonists
  • Indoles
  • ropinirole
  • Animals
  • Antiparkinson Agents (therapeutic use)
  • Dopamine Agonists (therapeutic use)
  • Humans
  • Indoles (therapeutic use)
  • Parkinson Disease (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: